Կանադա - անգլերեն - Health Canada

auro pharma inc - fulvestrant - solution - 50mg - fulvestrant 50mg

Կանադա - անգլերեն - Health Canada

formative pharma inc. - fulvestrant - solution - 50mg - fulvestrant 50mg

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fulvestrant 50 mg/ml;  ;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml     excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant ever pharma is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: · previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant-aft is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age previously treated with endocrine therapy (antioestrogen or aromatase inhibitor), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

zydus lifesciences limited - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) -

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - fulvestrant 50 mg in 1 ml - monotherapy faslodex is indicated for the treatment of: combination therapy faslodex is indicated for the treatment of: faslodex is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with faslodex [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, faslodex can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data] . advise pregnant women of the potential risk to a fetus. the estimated backg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

sandoz inc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2)] . risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data ]. advise pregnant women of the potential

Իսրայել - անգլերեն - Ministry of Health

pharmalogic ltd - fulvestrant - solution for injection - fulvestrant 50 mg / 1 ml - fulvestrant - fulvestrant ever pharma 250 mg is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy,or* disease progression on endocrine therapy.combination therapy with palbociclib: fulvestrant ever pharma 250 mg is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)- negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - fulvestrant 250 mg/5 ml - solution for injection - 250 mg - fulvestrant 50 mg/ml - fulvestrant